Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amantadine/oseltamivir/ribavirin - Adamas Pharmaceuticals

Next Previous
Drug Profile

Amantadine/oseltamivir/ribavirin - Adamas Pharmaceuticals

Alternative Names: ADS-8902; Amantadine/ribavirine/oseltamivir; Oseltamivir/amantadine/ribavirin; Oseltamivir/ribavirin/amantadine; Ribavirin/amantadine/oseltamivir; Ribavirin/oseltamivir/amantadine

Latest Information Update: 02 Dec 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Adamas Pharmaceuticals
  • Developer Adamas Pharmaceuticals; National Institutes of Health (USA)
  • Class Acetamides; Adamantanes; Antivirals; Cyclohexenes; Esters; Furans; Organic bridged compounds; Ribonucleosides; Small molecules; Triazoles
  • Mechanism of Action Dopamine receptor agonists; Ion channel modulators; Neuraminidase inhibitors; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Influenza A virus H1N1 subtype; Influenza A virus infections

Most Recent Events

  • 24 Nov 2021 Adamas Pharmaceuticals has been acquired by Supernus Pharmaceuticals
  • 14 Sep 2017 Chemical structure information added
  • 18 May 2012 Discontinued - Phase-II for Influenza A virus infections in Canada (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top